STOCK TITAN

Equillium (EQ) SEC Filings, Oct 2025-Jan 2026

EQ NASDAQ

Equillium, Inc. filings document a clinical-stage biotechnology issuer focused on therapies for severe autoimmune and inflammatory disorders. The company’s disclosures cover EQ504, an investigational AhR modulator, along with operating results, financial condition, research and development priorities, and capital resources tied to biotechnology development.

Regulatory filings include 8-K material-event reports, proxy materials, and registration-related disclosures. These records address annual-meeting matters, board and compensation governance, equity awards, auditor changes, common-stock offering documents, material agreements, shareholder voting matters, and capital-structure information for EQ common stock listed on the Nasdaq Capital Market.

Rhea-AI Summary

Equillium, Inc. reported that its Chief Executive Officer, director and 10% owner, Bruce D. Steel, was granted an employee stock option on 01/07/2026. The option covers 1,750,000 shares of common stock at an exercise price of $1.31 per share and expires on 01/06/2036. According to the vesting terms, 25% of the shares vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, Steel beneficially holds 1,750,000 derivative securities directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
-
Rhea-AI Summary

Equillium, Inc. Principal Accounting Officer Tom Penny reported one stock sale and a new stock option grant. Penny sold 6,533 shares of common stock on January 8, 2026 at $1.29 per share, leaving him with no shares of common stock held directly after the sale. The filing notes these sales were made under a Rule 10b5-1 trading plan adopted on October 10, 2025, meaning they were pre‑scheduled rather than discretionary.

On January 7, 2026, Penny was granted an employee stock option to purchase 450,000 shares of Equillium common stock at an exercise price of $1.31 per share. The option vests over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, he holds 450,000 stock options directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
-
Rhea-AI Summary

An employee shareholder of EQ has filed a notice of proposed sale on Form 144 to sell 6,533 shares of common stock. The shares are to be sold through Maxim Group, with an aggregate market value of $8,427.00, on the NASDAQ, with an approximate sale date of 01/08/2026. These shares were acquired on 06/18/2024 under an Employee Stock Purchase Plan from the issuer and were paid for in cash on 12/12/2025. The company had 60,893,283 shares of common stock outstanding at the time referenced in the notice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.74%
Tags
other
Rhea-AI Summary

Equillium’s Senior Vice President and Chief Operating Officer reported open-market sales of company common stock. On December 12, 2025, the executive sold 23,804 shares of Equillium common stock at a price of $1.34 per share. On December 15, 2025, an additional 11,900 shares were sold at $1.31 per share.

Following these transactions, the reporting person beneficially owned 91,444 shares of Equillium common stock in direct ownership. The filing notes that the reported sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025, which is a pre-arranged plan for trading company stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
insider
-
Rhea-AI Summary

Equillium, Inc. (EQ) reported an insider stock sale by its Sr. Vice President and COO on a Form 4. On 11/25/2025, the officer sold 100 shares of common stock at $0.98 per share and another 7,998 shares at $0.95 per share. After these transactions, the officer beneficially owned 127,148 shares of Equillium common stock directly. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025, which is designed to allow insiders to sell shares according to a predetermined schedule.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.16%
Tags
insider
-
Form S-3
Rhea-AI Summary

Equillium, Inc. filed a shelf registration on Form S-3 to offer up to $250,000,000 of securities (common stock, preferred stock, debt, and warrants) from time to time, with terms to be set by prospectus supplements. The filing also includes a dedicated sales agreement prospectus for an at-the-market offering of up to $75,000,000 of common stock through LifeSci Capital, included within the $250,000,000 shelf.

Under the ATM, LifeSci Capital will act as sales agent on a commercially reasonable efforts basis, and will receive up to 3.0% of gross proceeds as compensation. Proceeds to the company will be used for general corporate purposes, including research and development, working capital, and capital expenditures, as later specified in supplements.

Equillium’s common stock trades on Nasdaq as “EQ,” and the last reported sale price was $0.924 per share on November 12, 2025. Shares outstanding were 60,676,837 as of September 30, 2025; this is a baseline figure, not the amount being offered.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.81%
Tags
registration
Rhea-AI Summary

Equillium, Inc. (EQ) reported a Q3 net loss of $4.23 million with $0 revenue, compared with $12.16 million in revenue a year ago tied to a now‑ended Ono arrangement. Operating expenses were $4.58 million versus $12.84 million last year, reflecting a smaller cost base post‑transition.

Cash and cash equivalents were $33.12 million and stockholders’ equity totaled $30.94 million. The company closed an August 2025 private placement for ~$30 million gross (common stock and pre‑funded warrants), and may raise up to an additional ~$20 million upon clinical and price‑based milestones. During Q3, it also sold shares via its ATM facility for ~$0.9 million gross. Shares outstanding were 60,676,837 at September 30, 2025, and 60,893,283 as of November 10, 2025.

The company terminated prior Biocon agreements and is focusing on EQ504, an aryl hydrocarbon receptor modulator, with an intended Phase 1 proof‑of‑mechanism study by mid‑2026. Management indicates existing cash is expected to fund operations through 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.81%
Tags
quarterly report
-
Rhea-AI Summary

Equillium, Inc. furnished an 8‑K announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1. The company states the information under Item 2.02, including the exhibit, is furnished and not deemed filed under Section 18 of the Exchange Act, and it is not incorporated by reference into other SEC filings except as expressly specified by reference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.81%
Tags
current report
-
Rhea-AI Summary

Equillium, Inc. filed an amended report to update its previously disclosed change in independent auditor. The company confirms that Crowe LLP has now completed its client acceptance procedures and, on October 21, 2025, executed an engagement letter to serve as Equillium’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

The company states that during the two most recent fiscal years ended December 31, 2024 and December 31, 2023, and through October 21, 2025, it did not consult with Crowe on specific accounting treatments, potential audit opinions, or any issues involving disagreements or reportable events under SEC rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
current report
Rhea-AI Summary

Equillium, Inc. filed a Form 8-K reporting a letter from independent auditor KPMG LLP dated October 6, 2025. The company states that KPMG reported no disagreements with management on accounting principles, financial statement disclosure, or audit scope, and identified no reportable events as defined under Regulation S‑K. A copy of KPMG's letter is attached as Exhibit 16.1. The filing also notes the Cover Page Interactive Data File is embedded with the Inline XBRL document. The report is signed by Bruce D. Steel, Chief Executive Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
current report

FAQ

How many Equillium (EQ) SEC filings are available on StockTitan?

StockTitan tracks 72 SEC filings for Equillium (EQ), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Equillium (EQ)?

The most recent SEC filing for Equillium (EQ) was filed on November 13, 2026.